Alpha 2.0
Login Register
» Authors » Ellen M Apperloo

Ellen M Apperloo

Explore the profile of Ellen M Apperloo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 12
Followers 0
Related Specialties
Endocrinology
General Medicine
General Surgery
Top 10 Co-Authors
Hiddo J L Heerspink
David Z I Cherney
Niels Jongs
Klaas Hoogenberg
Katherine R Tuttle
Christoph Wanner
Dick de Zeeuw
Soren Rasmussen
Natalie Staplin
Roland E Schmieder
Published In
Diabetes Care
Diabetes Obes Metab
Nat Med
Nephrol Dial Transplant
Lancet Diabetes Endocrinol
Affiliations
Soon will be listed here.
Recent Articles
1.
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial
Apperloo E, Heerspink H, van der Aart A, Rouw D, van Raalte D, Hoogenberg K, et al.
Diabetes Care . 2025 Jan; 48(3):e22-e24. PMID: 39792380
No abstract available.
2.
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials
Apperloo E, Tuttle K, Pavo I, Haupt A, Taylor R, Wiese R, et al.
Diabetes Care . 2025 Jan; 48(3):430-436. PMID: 39746157
Objective: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes and...
3.
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Apperloo E, Gorriz J, Soler M, Cigarran Guldris S, Cruzado J, Puchades M, et al.
Nat Med . 2024 Oct; 31(1):278-285. PMID: 39455729
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in...
4.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol . 2024 Jul; 12(8):545-557. PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...
5.
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
Apperloo E, Cherney D, Kuhlman A, Mann J, Rasmussen S, Rossing P, et al.
Nephrol Dial Transplant . 2024 Jul; 40(2):352-359. PMID: 38955363
Background: This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status...
6.
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
Apperloo E, Pena M, de Zeeuw D, Denig P, Heerspink H
Diabetes Obes Metab . 2018 Jan; 20(6):1377-1383. PMID: 29345404
Aims: To assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating renin angiotensin aldosterone system (RAAS)...